Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for Social Cognition in Schizophrenia
NCT02577575Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Aug 2010
- Primary completion
- Nov 2015
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in schizophrenia, sponsored by University of California, San Francisco. Primary endpoint: Improvement in social cognition task performance at 2 days. Started Aug 2010; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02577575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02577575.